KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Revenue (2016 - 2026)

Pacira BioSciences has reported Revenue over the past 17 years, most recently at $177.4 million for Q1 2026.

  • For Q1 2026, Revenue rose 5.0% year-over-year to $177.4 million; the TTM value through Mar 2026 reached $734.9 million, up 4.57%, while the annual FY2025 figure was $726.4 million, 3.63% up from the prior year.
  • Revenue for Q1 2026 was $177.4 million at Pacira BioSciences, down from $196.9 million in the prior quarter.
  • Over five years, Revenue peaked at $196.9 million in Q4 2025 and troughed at -$479.6 million in Q4 2022.
  • A 5-year average of $135.0 million and a median of $169.4 million in 2022 define the central range for Revenue.
  • Biggest five-year swings in Revenue: crashed 401.27% in 2022 and later skyrocketed 137.79% in 2023.
  • Year by year, Revenue stood at -$479.6 million in 2022, then skyrocketed by 137.79% to $181.2 million in 2023, then increased by 3.32% to $187.3 million in 2024, then increased by 5.14% to $196.9 million in 2025, then dropped by 9.9% to $177.4 million in 2026.
  • Business Quant data shows Revenue for PCRX at $177.4 million in Q1 2026, $196.9 million in Q4 2025, and $179.5 million in Q3 2025.